Simon Farrell
Known title: Chief Commercial OfficerCIK: 0001965585
Associated companies
Transaction History
| TRVI | ▲ Buy | Option Exercise | 63,813 | $250K | 3/10/2025 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 31,250 | $16K | 3/10/2025 | View on chart |
| TRVI | ▼ Sell | Open Market | 4,350 | $31K | 3/10/2025 | View on chart |
| TRVI | ▼ Sell | Open Market | 76,963 | $518K | 3/10/2025 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 17,500 | $56K | 3/10/2025 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 6,250 | $3K | 6/20/2023 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 18,750 | $10K | 3/7/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
TRVI releases Q2 2026 earnings and makes Raymond James top health list
Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.
TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.